Limertinib

DRUG3 trials

Sponsors

Shanghai Chest Hospital, Hunan Province Tumor Hospital, Innovent Biologics (Suzhou) Co. Ltd.

Conditions

EGFR Mutation Positive Advanced Non Small Cell Lung CancerNon Small Cell Lung CancerNon Small Cell Lung Cancer NSCLCPD-L1 PositiveSmall Cell Lung CancerSolid Tumor

Phase 1

Study of IBI3005 Combination Therapy in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors

Not yet recruitingNCT07612137

Innovent Biologics (Suzhou) Co. Ltd.Solid Tumor

Start: 2026-06-01End: 2028-06-30Target: 282Updated: 2026-05-28

Phase 2

A Clinical Study on the Efficacy and Safety of the Combination of Limertinib and Bevacizumab Versus Limertinib as First-line Treatment for NSCLC.

Not yet recruitingNCT06982924

Shanghai Chest HospitalEGFR Mutation Positive Advanced Non Small Cell Lung Cancer, PD-L1 Positive

Start: 2025-06-30End: 2028-12-30Target: 136Updated: 2025-05-21

Limertinib Plus Carboplatin and Etoposide for EGFR-mutant NSCLC With SCLC Transformation After EGFR-TKI Progression

Not yet recruitingNCT07001995

Hunan Province Tumor HospitalNon Small Cell Lung Cancer, Non Small Cell Lung Cancer NSCLC, Small Cell Lung Cancer

Start: 2026-05-01End: 2028-12-30Target: 30Updated: 2026-03-16